查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1878093

全球肺炎链球菌疫苗市场－2025年至2030年预测

Global Pneumococcal Vaccine Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 114 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球肺炎链球菌疫苗市场预计将从 2025 年的 100.58 亿美元成长到 2030 年的 136.07 亿美元，复合年增长率为 6.23%。

肺炎链球菌疫苗旨在预防由肺炎链球菌（肺炎链球菌）引起的疾病。虽然肺炎链球菌感染在幼儿中更为常见，但成人和老年人感染后严重感染甚至死亡的风险更高。接种疫苗被广泛认为是预防这些疾病传播的重要公共卫生措施，支持了肺炎疫苗的稳定需求。市场扩张得益于几个关键因素，包括基于国家政策实施的常规免疫规划、公众对肺炎认识的提高，以及世界卫生组织（WHO）和联合国儿童基金会（UNICEF）等国际组织的策略指南（通常辅以政府的大力支持）。

主要市场成长驱动因素

全球肺炎链球菌疫苗市场的主要驱动因素是儿童肺炎的高发生率。在所有影响儿童的感染疾病中，肺炎是全球儿童死亡的首要原因。高死亡率，尤其是在五岁以下婴幼儿中，使得遏制儿童死亡成为一项紧迫的公共卫生挑战。这种严峻形势推动了对有效预防措施的需求，从而刺激了肺炎球菌疫苗市场的成长。南亚、西非和中非等某些地区的肺炎发生率尤其高，进一步凸显了广泛进行疫苗接种活动的必要性。

同时，疾病防治宣传活动的扩大和政府政策的支持也为市场带来了新的成长机会。肺炎链球菌疫苗主要用于预防儿童肺炎，国际组织正与各国政府合作，降低感染率，尤其是在弱势族群。国家疫苗接种计划的实施，例如在全民免疫倡议下扩大肺炎球菌结合疫苗（PCV）的接种范围，旨在提高公众意识并增强儿童的免疫系统。这些计划和政策透过鼓励新产品的推出和现有产品组合的扩展，刺激了疫苗市场的发展。此外，国际组织对肺炎负担沉重的开发中国家的支持，透过改善疫苗的可近性，也促进了市场的成长趋势。

市场区隔分析

全球肺炎链球菌疫苗市场依类型分为结合疫苗和多醣体疫苗。预计结合疫苗市场将实现显着成长。此细分市场的扩张主要得益于疫苗在预防肺炎和脑膜炎等严重的有效性，这些疾病主要影响婴幼儿和老年人。持续不断的疫苗研发工作不断提升疫苗的效力，新核准也扩大了对更多肺炎链球菌血清型的保护范围，从而持续推动该细分市场的成长。

本报告按地区分析了北美、南美、欧洲、中东和非洲以及亚太地区的市场。北美预计将占据显着的市场份额。这一主导地位得益于各方为遏制儿童和成人肺炎传播所做的共同努力，促使监管机构核准了新型先进疫苗。此外，众多生技和製药公司积极参与疫苗研发，进一步巩固了该地区的市场地位。肺炎链球菌疫苗的持续研发，以及疾病的持续蔓延，将继续推动北美市场的整体成长。

市场限制

全球肺炎链球菌疫苗市场面临的主要阻碍因素是疫苗生产高成本。疫苗研发过程不仅耗资巨大，而且耗时漫长，因为必须经过多个阶段的严格测试和监测，以确保其安全性和有效性。这种耗时耗资的特性对市场成长构成了重大挑战。然而，政府对疫苗生产的补贴以及国际组织的资助在一定程度上缓解了这一障碍，这些资金支持了疫苗的研发和分发。

主要市场趋势

市场特征是主要企业持续活跃，专注于先进候选疫苗的研发和商业化。近期策略进展包括监管机构对新型疫苗的正面评价，这些疫苗能够扩大对侵袭性疾病的保护范围，涵盖从婴幼儿到成人的广泛年龄层。此外，各公司已达成商业生产协议，以加强肺炎链球菌结合疫苗候选产品的生产和商业化。这些合作利用了现有的生产基础设施和专业技术，扩大了供应，满足了全球需求，体现了充满活力且面向未来的产业格局。

本报告的主要优势：

  • 深入分析：提供对主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、行业垂直领域和其他细分市场。
  • 竞争格局：了解全球主要企业的策略倡议，并了解透过正确的策略实现市场渗透的潜力。
  • 市场驱动因素与未来趋势：探讨影响市场的动态因素和关键趋势及其对未来市场发展的影响。
  • 可操作的建议：利用这些见解，在快速变化的环境中製定策略决策，发展新的商业机会和收入来源。
  • 受众广泛：适用于Start-Ups、研究机构、顾问公司、中小企业和大型企业，且经济实惠。

企业使用我们的报告的目的是什么？

产业与市场分析、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法规结构及影响、新产品开发、竞争情报

报告范围：

  • 2022年至2024年的历史数据和2025年至2030年的预测数据
  • 成长机会、挑战、供应链前景、法规结构与趋势分析
  • 竞争定位、策略和市场占有率分析
  • 按业务板块和地区分類的收入成长和预测评估，包括国家/地区
  • 公司概况（策略、产品、财务资讯、关键发展等）

全球肺炎链球菌疫苗市场已按以下方式进行细分和分析：

  • 肺炎链球菌疫苗市场按类型划分
  • 结合疫苗
  • 多醣体疫苗
  • 按应用分類的肺炎链球菌疫苗市场
  • 常规疫苗接种
  • 疾病及感染疾病接种
  • 按地区分類的肺炎链球菌疫苗市场
  • 北美洲
  • 美国
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他的
  • 欧洲
  • 德国
  • 法国
  • 英国
  • 西班牙
  • 其他的
  • 中东和非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他的
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 印尼
  • 泰国
  • 其他的

目录

第一章执行摘要

第二章 市场概览

  • 市场概览
  • 市场定义
  • 调查范围

第二章 4. 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策与法规
  • 策略建议

第四章 技术展望

5. 肺炎链球菌疫苗市场（按类型划分）

  • 介绍
  • 结合疫苗
  • 多醣体疫苗

6. 按应用分類的肺炎链球菌疫苗市场

  • 介绍
  • 常规疫苗接种
  • 疫苗接种预防疾病及感染疾病

7. 各地区肺炎链球菌疫苗市场

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第八章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 合併、收购、协议和合作
  • 竞争对手仪錶板

第九章：公司简介

  • Pfizer
  • GSK
  • Merck
  • AstraZeneca
  • Serum Institute of India Pvt Ltd
  • Sanofi
  • CSL Limited
  • Walvax Biotechnology Co. Ltd

第十章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061611187

The global pneumococcal vaccine market is forecasted to rise at a 6.23% CAGR, reaching USD 13.607 billion by 2030 from USD 10.058 billion in 2025.

Pneumococcal vaccines are designed to prevent disease caused by the bacterium Streptococcus pneumoniae. While pneumococcal diseases are common in young children, adults and the elderly demonstrate a higher susceptibility to severe contamination and mortality. Immunization is widely recognized as a critical public health measure to prevent the spread of such diseases, thereby driving consistent demand for pneumonia vaccines. The market's expansion is supported by several key factors, including the implementation of regular vaccination programs under national policies, rising public awareness against pneumonia, and strategic directives launched by international bodies like the World Health Organization (WHO) and UNICEF, often backed by increasing government support.

Primary Market Growth Drivers

A significant driver for the global pneumococcal vaccine market is the substantial incidence of childhood pneumonia. Among all infectious diseases affecting children, pneumonia is a leading cause of mortality globally. The high number of fatalities, particularly among children under the age of five, creates an urgent public health imperative to combat child mortality rates. This alarming situation is expanding the demand for effective prophylactic measures, thereby stimulating market growth for pneumococcal vaccines. The incidence rates are notably higher in certain regions, such as South Asia and West and Central Africa, which further underscores the need for widespread vaccination efforts.

Concurrently, growing disease awareness campaigns and supportive government policies are providing new growth prospects. Pneumococcal vaccines are primarily administered to children to protect them from illness, prompting international organizations to collaborate with national governments to reduce infection rates, especially among vulnerable populations. The implementation of nationwide vaccine programs, such as the expansion of pneumococcal conjugate vaccine (PCV) under universal immunization initiatives, aims to spread awareness and boost children's immune systems. These plans and policies invigorate the vaccine market by facilitating the introduction of novel products and the expansion of existing portfolios. Furthermore, aid from international organizations to underdeveloped countries with high pneumonia prevalence rates is contributing to an upward market trajectory by increasing vaccine accessibility.

Market Segment Analysis

The global pneumococcal vaccine market is segmented by type into conjugate vaccines and polysaccharide vaccines. The conjugate vaccine segment is anticipated to demonstrate remarkable growth. This segment's expansion is fueled by the vaccine's efficacy in providing immunity against serious diseases such as pneumonia and meningitis, which predominantly affect infants and older adults. Ongoing research and development efforts to enhance these vaccines continue to provide a major boost to the segment's growth, with new approvals expanding their protective coverage against a broader range of pneumococcal serotypes.

Geographically, the market is analyzed across North America, South America, Europe, the Middle East and Africa, and the Asia Pacific. North America is estimated to constitute a remarkable market share. This dominance is fueled by concerted efforts to reduce the spread of pneumonia among children and adults, leading regulatory authorities to grant approvals for new and advanced vaccines. The presence of major biotech and pharmaceutical manufacturers actively engaged in vaccine development further solidifies the region's market position. The ongoing development of pneumococcal vaccines, coupled with the persistent prevalence of the disease, continues to drive overall market growth in North America.

Market Restraints

A primary restraint on the global pneumococcal vaccine market is the high cost associated with vaccine production. The process of developing a vaccine is not only expensive but also involves a long duration, requiring passage through various phases of rigorous testing and monitoring to ensure safety and efficacy. This time-consuming and capital-intensive nature presents a significant challenge to market growth. However, this hurdle is partially mitigated by government subsidies for vaccine production and funds released by international organizations, which help to support the development and distribution pipeline.

Key Market Developments

The market is characterized by continuous activity from key players, focusing on the development and commercialization of advanced vaccine candidates. Recent strategic developments include positive regulatory opinions for new vaccines that offer broader protection against invasive diseases across various age groups, from infants to adults. Furthermore, companies are entering into commercial manufacturing agreements to bolster the production and commercialization of their pneumococcal conjugate vaccine candidates. Such collaborations leverage established manufacturing infrastructure and expertise to ensure scalable supply and meet global demand, reflecting a dynamic and forward-looking industry landscape.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

The Global Pneumococcal Vaccine market is segmented and analyzed as follows:

  • PNEUMOCOCCAL VACCINES MARKET BY TYPE
  • Conjugate Vaccines
  • Polysaccharide Vaccines
  • PNEUMOCOCCAL VACCINES MARKET BY APPLICATION
  • Routine Vaccination
  • Vaccination For Disease/Infection
  • PNEUMOCOCCAL VACCINES MARKET BY GEOGRAPHY
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. PNEUMOCOCCAL VACCINES MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Conjugate Vaccines
  • 5.3. Polysaccharide Vaccines

6. PNEUMOCOCCAL VACCINES MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Routine Vaccination
  • 6.3. Vaccination For Disease/Infection

7. PNEUMOCOCCAL VACCINES MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. USA
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. Germany
    • 7.4.2. France
    • 7.4.3. United Kingdom
    • 7.4.4. Spain
    • 7.4.5. Others
  • 7.5. Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. UAE
    • 7.5.3. Others
  • 7.6. Asia Pacific
    • 7.6.1. China
    • 7.6.2. India
    • 7.6.3. Japan
    • 7.6.4. South Korea
    • 7.6.5. Indonesia
    • 7.6.6. Thailand
    • 7.6.7. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Pfizer
  • 9.2. GSK
  • 9.3. Merck
  • 9.4. AstraZeneca
  • 9.5. Serum Institute of India Pvt Ltd
  • 9.6. Sanofi
  • 9.7. CSL Limited
  • 9.8. Walvax Biotechnology Co. Ltd

10. APPENDIX

  • 10.1. Currency
  • 10.2. Assumptions
  • 10.3. Base and Forecast Years Timeline
  • 10.4. Key Benefits for the Stakeholders
  • 10.5. Research Methodology
  • 10.6. Abbreviations